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   – Atoneweekpost-op,16.7%(3/18)ofpatientshadnodata;40%(6/15)werewithinrange.
   – At30dayspost-op,5.6%(1/18)ofpatientshadnodata;23.5%(4/17)werewithinrange.
   – At60dayspost-op,16.7%(3/18)ofpatientshadnodata;46.7%(7/15)werewithinrange.





















   – 22.2%(4/18)ofpatientsdidnotreportapre-operationINR.
   – 92.9%(13/14)ofremainingpatientswerewithintheoptimalrange.


























INRs and BMIs of Chronic Coumadin Users 











































































PR E-OP IN R
1-W EEK IN R
30-DAY INR
60-DAY INR
6-MO N TH IN R
Patient Identification Number 


Table 1.   INRs and Coumadin Dosages of Chronic Coumadin Users Pre- and Post- Bariatric Surgery
Patient ID 
Number    PRE-OP 1 WEEK 30 DAYS 60 DAYS 6 MONTHS
PT 16
INR 1.1 1.2 3.7 2.5 3.2
Coumadin Dose alt. 7.5mg/10mg 5mg alt. 7.5mg/10mg 7.5mg 7.5mg
PT 11
INR 1.3 3.5 2.9 2.1 2.0
Coumadin Dose cyc. 5mg/2.5mg cyc. 5mg/2.5mg cyc. 5mg/2.5mg cyc. 5mg/2.5mg cyc. 5mg/2.5mg
PT 17
INR 1.3 2.2 3.4 1.3 3.7
Coumadin Dose 5mg 5mg cyc. 5mg/2.5mg cyc. 5mg/2.5mg 5mg
PT 5
INR N/A N/A 1.6 1.8 1.7
Coumadin Dose 5mg N/A cyc. 5mg/7.5mg cyc. 5mg/7.5mg cyc. 5mg/7.5mg
PT 2
INR 1.4 1.7 3.6 N/A 1.5
Coumadin Dose cyc. 5mg/7.5mg cyc. 7.5mg/5mg cyc. 5mg/7.5mg N/A cyc. 7.5mg/5mg
PT 7
INR N/A 2.0 3.2 2.3 2.1
Coumadin Dose 3mg 3mg 3mg cyc. 3mg/2mg 3mg
PT 13
INR N/A 6.2 3.1 1.3 1.3
Coumadin Dose 5mg 5mg 5mg cyc. 5mg/2.5mg cyc. 5mg/2.5mg
PT 12
INR 1.3 1.1 2.5 2.3 2.6
Coumadin Dose 2mg + 100mg LMWH 2mg 3mg 2.5mg 2.5mg
PT 6
INR 1.0 N/A 1.7 N/A 1.8
Coumadin Dose 10mg N/A N/A 10mg N/A
PT 9
INR N/A 2.1 2.2 1.7 2.0
Coumadin Dose 5mg cyc. 1mg/5mg cyc. 2.5mg/5mg 5mg cyc. 7.5mg/5mg
PT 3
INR 1.9 3.0 3.5 2.5 4.0
Coumadin Dose 7mg 7mg 7mg 6mg alt. 9mg/6mg
PT 18
INR 1.3 1.5 4.5 1.1 12.5
Coumadin Dose 5mg + 125mg LMWH 7.5mg alt. 2.5mg/5mg 2.5mg 5mg
PT 8
INR 1.2 2.4 2.0 2.8 2.5
Coumadin Dose 11mg + 190mg LMWH cyc. 11mg/12mg cyc. 11mg/12mg cyc. 11mg/10mg cyc. 11mg/10mg
PT 14
INR 1.1 2.8 5.8 1.7 2.0
Coumadin Dose cyc. 15mg/14mg cyc. 15mg/14mg HOLD 11mg 11mg
PT 10
INR 1.1 3.3 5.7 1.4 2.9
Coumadin Dose cyc. 4.5mg/5mg 4mg 3mg 2.5mg 3.5mg
PT 4
INR 1.2 2.8 2.3 4.0 2.1
Coumadin Dose 4mg + 150mg/LMWH 2mg 1mg 1mg 1.5mg
PT 1
INR 1.1 N/A N/A N/A N/A
Coumadin Dose cyc. 10mg/2.5mg 12.5mg D/C’d-bleeding D/C’d-bleeding D/C’d-bleeding
PT 15
INR 1.1 3.9 1.4 2.0 3.7
Coumadin Dose cyc. 6mg/7mg + 150mg LMWH cyc. 6mg/7mg 6mg cyc. 6mg/3mg cyc. 5mg/7.5mg
TO TA L PAT IE N T S
N =1338
N O N -A N T IC O A G U LAT E D
PAT IE N T S
N =1294
A N T IC O A G U LAT E D
PAT IE N T S
N =44
E X C LU D E D PAT IE N T S
N =26
IN C LU D E D PAT IE N T S
N =18
PAT IE N T S R E A D M IT T E D
FO R H E M O R R H A G E
N =4
PAT IE N T S R E A D M IT T E D
FO R H E M O R R H A G E
N =3
Table 2.   Patients Readmitted Due 
                Hemorrhagic Complications
Patient ID Number   Readmittance Day
4 36
1 26
15 25
19 29
20 35
21 14
22 26
